Vu, Therese http://orcid.org/0000-0003-2831-2957
Straube, Jasmin http://orcid.org/0000-0002-1748-0659
Porter, Amy H.
Bywater, Megan
Song, Axia
Ling, Victoria http://orcid.org/0000-0001-9757-1229
Cooper, Leanne
Pali, Gabor
Bruedigam, Claudia
Jacquelin, Sebastien http://orcid.org/0000-0001-5087-3641
Green, Joanne
Magor, Graham
Perkins, Andrew http://orcid.org/0000-0003-3644-7093
Chalk, Alistair M. http://orcid.org/0000-0002-9630-6236
Walkley, Carl R. http://orcid.org/0000-0002-4784-9031
Heidel, Florian H.
Mukhopadhyay, Pamela
Cloonan, Nicole
Gröschel, Stefan
Mallm, Jan-Philipp http://orcid.org/0000-0002-7059-4030
Fröhling, Stefan http://orcid.org/0000-0001-7907-4595
Scholl, Claudia
Lane, Steven W. http://orcid.org/0000-0002-8050-6209
Article History
Received: 5 August 2019
Accepted: 28 May 2020
First Online: 15 June 2020
Competing interests
: We have the following disclosures that have been included in the manuscript as potential for conflict of interest. This work was funded by the National Health and Medical Research Fund of Australia and the Leukaemia Foundation of Australia. Celgene provided azacitidine and additional research funding. S.W.L. has participated in an advisory board for Celgene.